Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties

Triptans are presently a milestone in the treatment of migraine patients. Because of their effectiveness and safety, they have radically improved migraine treatment but their use has meant a substantial increase in spending for medicines. We compared available pharmaceutical forms, pack sizes, indic...

Descripción completa

Detalles Bibliográficos
Autores principales: Stirparo, Giuseppe, Palazzo, Fabio, De Filippis, Sergio, Martelletti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag Italia 2003
Materias:
Selected Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611693/
http://dx.doi.org/10.1007/s101940300019
_version_ 1782264563731791872
author Stirparo, Giuseppe
Palazzo, Fabio
De Filippis, Sergio
Martelletti, Paolo
author_facet Stirparo, Giuseppe
Palazzo, Fabio
De Filippis, Sergio
Martelletti, Paolo
author_sort Stirparo, Giuseppe
collection PubMed
description Triptans are presently a milestone in the treatment of migraine patients. Because of their effectiveness and safety, they have radically improved migraine treatment but their use has meant a substantial increase in spending for medicines. We compared available pharmaceutical forms, pack sizes, indications and dosages of triptans as listed in the summary of product characteristics of eight countries. We found that several differences exist between countries in the presentations of the triptans and in their licensing.
format Online
Article
Text
id pubmed-3611693
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Springer-Verlag Italia
record_format MEDLINE/PubMed
spelling pubmed-36116932013-04-01 Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties Stirparo, Giuseppe Palazzo, Fabio De Filippis, Sergio Martelletti, Paolo J Headache Pain Selected Presentation Triptans are presently a milestone in the treatment of migraine patients. Because of their effectiveness and safety, they have radically improved migraine treatment but their use has meant a substantial increase in spending for medicines. We compared available pharmaceutical forms, pack sizes, indications and dosages of triptans as listed in the summary of product characteristics of eight countries. We found that several differences exist between countries in the presentations of the triptans and in their licensing. Springer-Verlag Italia 2003-03 /pmc/articles/PMC3611693/ http://dx.doi.org/10.1007/s101940300019 Text en © Springer-Verlag Italia 2003
spellingShingle Selected Presentation
Stirparo, Giuseppe
Palazzo, Fabio
De Filippis, Sergio
Martelletti, Paolo
Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties
title Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties
title_full Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties
title_fullStr Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties
title_full_unstemmed Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties
title_short Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties
title_sort discrepancies between european countries and usa and canada in the availability of triptans and in their licensed clinical properties
topic Selected Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611693/
http://dx.doi.org/10.1007/s101940300019
work_keys_str_mv AT stirparogiuseppe discrepanciesbetweeneuropeancountriesandusaandcanadaintheavailabilityoftriptansandintheirlicensedclinicalproperties
AT palazzofabio discrepanciesbetweeneuropeancountriesandusaandcanadaintheavailabilityoftriptansandintheirlicensedclinicalproperties
AT defilippissergio discrepanciesbetweeneuropeancountriesandusaandcanadaintheavailabilityoftriptansandintheirlicensedclinicalproperties
AT martellettipaolo discrepanciesbetweeneuropeancountriesandusaandcanadaintheavailabilityoftriptansandintheirlicensedclinicalproperties

Ejemplares similares